Literature DB >> 15891959

Salivary cortisol measurement--a reliable method for the diagnosis of Cushing's syndrome.

M Trilck1, J Flitsch, D K Lüdecke, R Jung, S Petersenn.   

Abstract

The measurement of cortisol in saliva is becoming more widely accepted as a screening test for the diagnosis of hypercortisolism. Since 1986, cortisol measurement in saliva has been continuously used in our department. In this study we compared salivary cortisol profiles from proven Cushing's disease patients with profiles from healthy subjects and obese children. The purpose was to evaluate the predictive value of the method for the diagnosis of hypercortisolism and to define cut-off levels to exclude or identify hypercortisolism. Cortisol in saliva was measured in 150 Cushing's disease patients (30 children, 120 adults, ranging from age 4-70), 100 healthy subjects (55 children, 45 adults, ranging from age 6-60), and 31 children (age 7-15) with an age-related body-mass-index above the 90th percentile. Generally, five saliva samples were taken over the day at 6:00-8:00 a.m., 11:00-12:00 a.m., 4:00-6:00 p.m., 7:00-8:00 p.m., and 10:00 p.m. The samples were measured using a radioimmuno-assay (INCSTAR Corporation, Stillwater, Minnesota, USA). For healthy subjects, morning levels of cortisol in saliva between 3-19 microg/l were found. These levels dropped to levels in between <1-11 microg/l at 11:00-12:00 a.m., <1-6 microg/l at 4:00-6:00 p.m., <1-4.5 microg/l at 7:00-8:00 p.m., and <1-2.9 microg/l at 10:00 p.m. The measured values showed a correlation with age, height, and weight. In Cushing's disease patients, the circadian salivary cortisol rhythm was missing, compared to healthy subjects. There was no significant difference in salivary cortisol levels or circadian rhythm between healthy or obese children. We found a high sensitivity for the detection of hypercortisolism at the 10:00 p.m. salivary cortisol measurement. The following, age dependent cut-off levels for salivary cortisol at 10:00 p.m. were calculated for the exclusion of hypercortisolism. Age 6-10: 1.0 microg/l (specificity 100%, sensitivity 87.5%); age 11-15: 1.7 microg/l (specificity 100%, sensitivity 100%); age 16-20: 1.6 microg/l (specificity 100%, sensitivity 76.2%); age 21-60: 1.6 microg/l (specificity 100%, sensitivity 90.9%) [corrected] For the proof of Cushing's syndrome, the following age-dependent cut-off levels at 10:00 p.m. were found: age 6-10: 1.9 microg/l (specificity 100%, sensitivity 80%); age 11-15: 1.7 microg/l (specificity 100%, sensitivity 100%); age 16-20: 2.5 microg/l (specificity 100%, sensitivity 84.2%); age 21-60: 1.9 microg/l (specificity 100%, sensitivity 97.6 %) [corrected] The cortisol assessment in saliva is a sensitive and reliable method to discriminate normocortisolemic from hypercortisolemic patients. From our view, the major advantages of this method are the reliability, non-invasiveness, and use in ambulatory patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15891959     DOI: 10.1055/s-2005-837667

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  12 in total

1.  Reproducibility and performance of one or two samples of salivary cortisol in the diagnosis of Cushing's syndrome using an automated immunoassay system.

Authors:  C A Carrasco; M García; M Goycoolea; J Cerda; J Bertherat; O Padilla; D Meza; N Wohllk; T Quiroga
Journal:  Endocrine       Date:  2012-01-24       Impact factor: 3.633

2.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; John Newell-Price; Martin O Savage; Paul M Stewart; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2008-03-11       Impact factor: 5.958

3.  Serum but not salivary cortisol levels are influenced by daily glycemic oscillations in type 2 diabetes.

Authors:  Giuseppe Bellastella; Maria Ida Maiorino; Annamaria De Bellis; Maria Teresa Vietri; Carmela Mosca; Lorenzo Scappaticcio; Daniela Pasquali; Katherine Esposito; Dario Giugliano
Journal:  Endocrine       Date:  2015-10-28       Impact factor: 3.633

4.  Specificity of late-night salivary cortisol measured by automated electrochemiluminescence immunoassay for Cushing's disease in an obese population.

Authors:  J Aberle; C Schulze Zur Wiesch; J Flitsch; J Veigel; G Schön; R Jung; F Reining; A Lautenbach; R Rotermund; N Riedel
Journal:  J Endocrinol Invest       Date:  2018-03-17       Impact factor: 4.256

5.  Midnight salivary cortisol for the diagnosis of Cushing's syndrome in a Chinese population.

Authors:  Dao-Chen Lin; Pei-Shan Tsai; Yi-Chun Lin
Journal:  Singapore Med J       Date:  2018-11-29       Impact factor: 1.858

6.  Salivary cortisol and DHEA levels in the Korean population: age-related differences, diurnal rhythm, and correlations with serum levels.

Authors:  Ryun-Sup Ahn; Young-Jin Lee; Jun-Young Choi; Hyuk-Bang Kwon; Sae-Il Chun
Journal:  Yonsei Med J       Date:  2007-06-30       Impact factor: 2.759

7.  Neuropsychological and hypothalamic-pituitary-axis function in female patients with melancholic and non-melancholic depression.

Authors:  Ioannis Michopoulos; Iannis M Zervas; Chris Pantelis; Eleftheria Tsaltas; Vassiliki-Maria Papakosta; Fotini Boufidou; Chrissoula Nikolaou; Charalambos Papageorgiou; Costas R Soldatos; Lefteris Lykouras
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-06       Impact factor: 5.270

Review 8.  Cushing syndrome.

Authors:  Bibek Bista; Nancy Beck
Journal:  Indian J Pediatr       Date:  2013-09-24       Impact factor: 1.967

Review 9.  Saliva-based biosensors: noninvasive monitoring tool for clinical diagnostics.

Authors:  Radha S P Malon; Sahba Sadir; Malarvili Balakrishnan; Emma P Córcoles
Journal:  Biomed Res Int       Date:  2014-09-08       Impact factor: 3.411

10.  Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study.

Authors:  James W Findling; Maria Fleseriu; John Newell-Price; Stephan Petersenn; Rosario Pivonello; Albert Kandra; Alberto M Pedroncelli; Beverly M K Biller
Journal:  Endocrine       Date:  2016-05-21       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.